CIK 0001650648 · Non-accelerated filer<br>Smaller reporting company
4D Molecular Therapeutics, Inc.
Sign in to watch- Ticker
- FDMT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 473506994
- Phone
- 5105052680
- Business address
- 5858 HORTON STREET #455, EMERYVILLE, CA, 94608
- Former names
- 4D Molecular Therapeutics Inc., 4D Molecular Therapeutics Inc
- 4 Planned sale Chief Executive Officer sold 12,930 shares at $23.10 ($298,711)
- 4 Planned sale Chief Legal Officer sold 1,750 shares at $23.71 ($41,494)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Chief Legal Officer sold 1,750 shares at an average $25.45 ($44,541)
- 4 Planned sale Chief Legal Officer sold 1,750 shares at $25.74 ($45,045)
- 4 Planned sale Chief Legal Officer sold 8,153 shares at $31.78 ($259,102)
- 4 Planned sale Chief Legal Officer sold 5,833 shares at $35.04 ($204,410)
- 4 Planned sale Chief Legal Officer sold 1,750 shares at $31.27 ($54,723)
- 4 Planned sale Chief Legal Officer sold 1,909 shares at $30.00 ($57,270)
- 4 Planned sale Chief Legal Officer sold 1,750 shares at $27.67 ($48,423)
- 4 Planned sale Chief Legal Officer sold 6,244 shares at $27.50 ($171,710)
- 4 Planned sale Chief Executive Officer sold 92,001 shares at $27.13 ($2,495,822)
- 4 Planned sale Chief Medical Officer sold 24,552 shares at $30.05 ($737,788)
- 3/A Insider 3/A
- 4 Open-market sale Chief Executive Officer sold 5,696 shares at $18.41 ($104,851)
Page 4 of 9 · 170 filings